ImmunityBio gains as NCCN guidelines include new Anktiva indication

1 hour ago

On the Move

Comments

ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of its bladder cancer therapy, Anktiva.

Citing the updated 2026 NCCN

Source seekingalpha

↑

ImmunityBio gains as NCCN guidelines include new Anktiva indication

Related Article

OpenAI signs deal with AWS to sell AI to US government workers: report

Upstart Secures $1B Forward-Flow Agreement with Eltura Capital and Aperture Investors

Where Will the Cryptocurrency XRP Be in 5 Years? An In-Depth Analysis